B-Lymphoblastic Leukemia with Aberrant CD5 Expression

Matthew T. Ye, Jia Zhu, David X. Luo, Yi Wang, Zehui Chen, Yaling Yang, Chen Tian, Yizhuo Zhang, M. James You

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: B-acute lymphoblastic leukemia (B-ALL) is a neoplasm of precursor lymphoid cells committed to the B-lineage. Expression of CD5 is rare in B-ALL. Methods: We studied the clinicopathologic, immunophenotypic, and molecular genetic features of 10 cases of B-ALL with aberrant CD5 expression, and compared with CD5-B-ALL. Results: B-ALL with aberrant CD5 expression is rare and predominantly affects men. Patients with CD5+ B-ALL had shorter median overall survival (21 vs 45 months, P =. 0003). Expression of CD5 imposed a challenge in the differential diagnoses between B-ALL and other CD5+ B-cell lymphomas with blastic morphology. Dim CD20 and CD45, lack of surface immunoglobulin, expression of CD34 and TdT, negative immunostain for cyclin D1, and absence of t(11;14)(q13;q32) support a diagnosis of B-ALL. Conclusions: CD5 expression is rare in B-ALL and associated with poor clinical outcome. CD5+ B-ALL represents a distinct entity that needs to be considered in the differential diagnoses of CD5+ B-cell lymphoproliferative disorders.

Original languageEnglish (US)
Pages (from-to)586-595
Number of pages10
JournalAmerican journal of clinical pathology
Volume156
Issue number4
DOIs
StatePublished - Oct 1 2021

Keywords

  • B-acute lymphoblastic leukemia
  • CD5
  • Short overall survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'B-Lymphoblastic Leukemia with Aberrant CD5 Expression'. Together they form a unique fingerprint.

Cite this